• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.

作者信息

Stamm Luisa M, Brainard Diana M, McHutchison John G

机构信息

Gilead Sciences, Inc., Foster City, CA, United States.

Gilead Sciences, Inc., Foster City, CA, United States.

出版信息

J Hepatol. 2019 Mar;70(3):561-562. doi: 10.1016/j.jhep.2018.08.029. Epub 2018 Nov 13.

DOI:10.1016/j.jhep.2018.08.029
PMID:30445102
Abstract
摘要

相似文献

1
Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.
J Hepatol. 2019 Mar;70(3):561-562. doi: 10.1016/j.jhep.2018.08.029. Epub 2018 Nov 13.
2
Reply to: "Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL recommendations on treatment of Hepatitis C 2018": EASL Recommendations on Treatment of Hepatitis C 2018: Precision on the treatment of patients with genotype 3a infection and compensated cirrhosis.
J Hepatol. 2019 Mar;70(3):562-564. doi: 10.1016/j.jhep.2018.11.004. Epub 2018 Nov 13.
3
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.索磷布韦和维帕他韦联合利巴韦林或不联合利巴韦林治疗丙型肝炎病毒基因型 3 感染合并肝硬化患者的疗效。
Gastroenterology. 2018 Oct;155(4):1120-1127.e4. doi: 10.1053/j.gastro.2018.06.042. Epub 2018 Jun 27.
4
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.索磷布韦、维帕他韦和 NS3/4A 蛋白酶抑制剂 GS-9857 联合治疗初治或经治的 1 型或 3 型丙型肝炎病毒感染患者的疗效。
Gastroenterology. 2016 Sep;151(3):448-456.e1. doi: 10.1053/j.gastro.2016.05.021. Epub 2016 May 27.
5
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.索磷布韦和维帕他韦治疗 1、2、4、5、6 型 HCV 感染。
N Engl J Med. 2015 Dec 31;373(27):2599-607. doi: 10.1056/NEJMoa1512610. Epub 2015 Nov 16.
6
Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.索磷布韦/维帕他韦：首款用于丙型肝炎的泛基因型直接抗病毒联合疗法
Ann Pharmacother. 2017 Jan;51(1):44-53. doi: 10.1177/1060028016668897. Epub 2016 Oct 1.
7
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.索磷布韦、维帕他韦和沃西拉韦治疗既往 HCV 感染。
N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.
8
Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.索磷布韦/维帕他韦/伏西瑞韦：一种用于丙型肝炎的泛基因型直接抗病毒联合疗法
Ann Pharmacother. 2018 Apr;52(4):352-363. doi: 10.1177/1060028017741508. Epub 2017 Nov 8.
9
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.索磷布韦和维帕他韦治疗 2 型和 3 型丙型肝炎病毒感染。
N Engl J Med. 2015 Dec 31;373(27):2608-17. doi: 10.1056/NEJMoa1512612. Epub 2015 Nov 17.
10
Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis?对于丙型肝炎病毒3型感染并伴有肝硬化的患者，利巴韦林在索磷布韦和维帕他韦治疗中仍有作用吗？
Gastroenterology. 2018 Oct;155(4):969-971. doi: 10.1053/j.gastro.2018.09.003. Epub 2018 Sep 8.

引用本文的文献

1
Revolution in the diagnosis and management of hepatitis C virus infection in current era.当前时代丙型肝炎病毒感染诊断与管理的变革
World J Hepatol. 2022 Apr 27;14(4):647-669. doi: 10.4254/wjh.v14.i4.647.
2
Breakthroughs in hepatitis C research: from discovery to cure.丙型肝炎研究的突破：从发现到治愈。
Nat Rev Gastroenterol Hepatol. 2022 Aug;19(8):533-550. doi: 10.1038/s41575-022-00608-8. Epub 2022 May 20.
3
Use of sofosbuvir based regimen in patients with end-stage renal disease and chronic hepatitis C; an open label, non-randomized, single arm, single center study from Pakistan.
基于索磷布韦的治疗方案在终末期肾病合并慢性丙型肝炎患者中的应用；一项来自巴基斯坦的开放标签、非随机、单臂、单中心研究。
Gastroenterol Hepatol Bed Bench. 2020 Spring;13(2):141-146.